Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001852102 | SCV002240118 | pathogenic | not provided | 2024-08-04 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 66 of the TREM2 protein (p.Thr66Met). This variant is present in population databases (rs201258663, gnomAD 0.04%). This missense change has been observed in individuals with autosomal dominant Alzheimer disease and/or autosomal recessive frontotemporal dementia (PMID: 23150934, 23318515, 24899047, 29557178). ClinVar contains an entry for this variant (Variation ID: 192242). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects TREM2 function (PMID: 24990881, 25615530, 28559417). For these reasons, this variant has been classified as Pathogenic. |
Institute for Human Genetics and Genomic Medicine, |
RCV004699120 | SCV005201049 | likely pathogenic | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2 | criteria provided, single submitter | clinical testing | The detected variant has a low frequency in gnomAD (0,005390 %) and ist only reported in heterozygous occurence. Bioinformatic predicition is deleterious (CaddPhred, SIFT, MutationTaster). The variant has been reported in literature before (PMID: 23318515, PMID: 24910390). It was classified as likely pathogenic (PS1, PM1, PM2, PM3). | |
Gene |
RCV000192213 | SCV000223798 | not provided | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 | no assertion provided | literature only |